Sequential treatment of melanoma patients who progressed on interleukin-2 and dacarbazine by alpha-interferon and dacarbazine--a preliminary report.

O. Merimsky, M. Inbar, E. Shiloni, I. Ron, S. Chaitchik

Research output: Contribution to journalArticlepeer-review

Abstract

alpha-Interferon, 3 x 10(6) U/m2 every other day, and dacarbazine, up to 800 mg/m2 every 3 weeks, were given to nine patients with metastatic malignant melanoma who had progressed on a combination of interleukin-2 and dacarbazine. Partial response was documented in two patients for 9 and 4 months. Responsive sites were the lungs, lymph nodes, liver, and skin. Failure to respond to one biologic response modifier does not predict the response to another modifier.

Original languageEnglish
Pages (from-to)208-210
Number of pages3
JournalMolecular biotherapy
Volume2
Issue number4
StatePublished - Dec 1990
Externally publishedYes

Fingerprint

Dive into the research topics of 'Sequential treatment of melanoma patients who progressed on interleukin-2 and dacarbazine by alpha-interferon and dacarbazine--a preliminary report.'. Together they form a unique fingerprint.

Cite this